New evidence indicates vitiligo-associated autoimmunity may contribute to reduced morbidity and mortality risk

According to a new study comparing patients with and without vitiligo in South Korea, patients with vitiligo were associated with a 25% decreased risk of mortality compared with controls. This suggests that vitiligo-associated autoimmunity may play a role in reducing morbidity and mortality. The results 新しいタブ／ウィンドウで開く appear in the Journal of Investigative Dermatology 新しいタブ／ウィンドウで開く, published by Elsevier.

Previous studies have documented a reduced risk of cancer in patients with vitiligo, however, there has been limited research on the relationship between vitiligo-associated autoimmunity and the risk of morbidity and mortality among patients with vitiligo.

Lead investigator Jung Min Bae, MD, PhD, Department of Dermatology, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, explains: "As a clinician, one of my goals is to conduct research that can encourage my patients with vitiligo. It was interesting to find that immunotherapy used in cancer treatment often induces autoimmune side-effects like vitiligo. My colleagues and I hypothesized that vitiligo, which is an autoimmune disorder, could have a protective effect against cancer. Our research shows that patients with vitiligo were associated with a 25% decreased risk of mortality compared to the controls, suggesting that vitiligo-associated autoimmunity may contribute to reduced morbidity and mortality."

The mortality of patients with vitiligo was investigated in a population-based cohort using the National Health Insurance Service (NHIS) database and the National Death Registry in South Korea. All-cause and cause-specific mortality were compared between patients with vitiligo and controls. In total, 107,424 patients with incident vitiligo and 537,120 matched controls were included. The mortality rates were 34.8 and 45.3 per 10,000 person-years in patients and controls, respectively. In addition to cancer, other cause-specific mortality including infectious diseases, hematologic diseases, endocrine diseases, neurologic diseases, cardiovascular diseases, respiratory diseases, and renal/urogenital disease was lower in patients with vitiligo.

Caption: A new study published in the Journal of Investigative Dermatology has determined that patients with vitiligo were associated with a lower risk of mortality, suggesting that vitiligo-associated autoimmunity may contribute to reduced morbidity and mortality (Credit: iStock.com/FG Trade).

According to co-lead investigator Solam Lee, MD, PhD, Department of Dermatology, Yonsei University Wonju College of Medicine: "The strength of our study is the utilization of the large NHIS database, which provides comprehensive information about patient BMI, lifestyles, comorbidities, laboratory findings, and linkage with death certificates. The study employed various statistical methods to reduce the potential bias, which makes the results more robust."

Whether these findings are attributable to the autoimmune mechanism of vitiligo itself or to unexpected effects of vitiligo treatment modalities (e.g., phototherapy) remains to be clarified in future studies.

First author Hyun Jeong Ju, MD, PhD, Department of Dermatology, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, adds: "Our findings are significant because they suggest that the autoimmune nature of vitiligo may confer certain protective effects against various causes of mortality, and they offer new avenues for research into the mechanisms underlying this protective effect. Moreover, understanding the mortality risk in patients with vitiligo will lead to improved patient counseling, health monitoring, and overall management strategies for patients."

Vitiligo is a chronic skin disorder characterized by depigmented patches; worldwide prevalence is estimated at 0.5-2% of the general population. Multiple factors contribute to the pathogenesis of vitiligo including susceptibility to oxidative stress, functional abnormalities of melanocytes, adhesion defect between melanocytes and keratinocytes, and autoreactive cytotoxic T cells.

---

Notes for editors

The article is “All-cause and cause-specific mortality among patients with vitiligo: A nationwide population-based study in Korea,” by Hyun Jeong Ju, Hyun Kang, Ju Hee Han, Ji Hae Lee, Solam Lee, and Jung Min Bae (https://doi.org/10.1016/j.jid.2023.07.007 新しいタブ／ウィンドウで開く). It appears online in the Journal of Investigative Dermatology, published by Elsevier.

The article is openly available at https://www.jidonline.org/article/S0022-202X(23)02481-8/fulltext 新しいタブ／ウィンドウで開く.

Full text of the article is also available to credentialed journalists upon request. Contact Theresa Monturano, at +1 215 239 3711 or [email protected] 新しいタブ／ウィンドウで開く to request a PDF of the article. Journalists wishing to interview the authors should contact Jung Min Bae, MD, PhD, at [email protected] 新しいタブ／ウィンドウで開く.

About Journal of Investigative Dermatology

The Journal of Investigative Dermatology 新しいタブ／ウィンドウで開く (JID) is the official journal of the Society of Investigative Dermatology and the European Society for Dermatological Research. JID publishes high-impact reports describing original research related to all aspects of cutaneous biology and skin diseases. Descriptions of important findings that result from basic, translational, or clinical research are published. Clinical research can include, but is not limited to, interventional trials, genetics studies, epidemiology, and health services research. www.jidonline.org 新しいタブ／ウィンドウで開く

エルゼビアについて

エルゼビアは情報分析を専門としたグローバル企業として、研究者や医療専門家の方々を支援し、社会にとっての利益最大化に向けて、科学や医療の進展を支えています。これは、信頼できるエビデンスによるコンテンツと高度なAI対応によるデジタル技術に基づく革新的なソリューションにより、知見の集積や重要な意思決定を支援することで実現されています。

エルゼビアは、全世界で9,700人の従業員（うち技術者2,300人以上）を抱え、140年以上にわたって、研究者、図書館員、アカデミックリーダー、資金提供者、政府、研究開発集約型企業、医師、看護師、将来の医療専門家、教育者など研究・医療分野におけるパートナーの重要な活動を支援してきました。エルゼビアが刊行する3,000誌以上の科学ジャーナルと代表的な参考書には、The Lancet 新しいタブ／ウィンドウで開く、Cell Press 新しいタブ／ウィンドウで開くおよびGray’s Anatomyなどをはじめとする、各分野を代表する主要なタイトルが含まれています。 エルゼビア・ファンデーション 新しいタブ／ウィンドウで開くとの活動を通し、私たちがサービスを提供する地域社会と連携して、開発途上国を含む世界中の医学、研究、医療分野における、インクルージョン＆ダイバーシティ（I&D）の改善に努めています。

エルゼビアは、専門家および企業向けの情報分析および意思決定ツールのグローバルプロバイダーであるRELX Group 新しいタブ／ウィンドウで開くの一事業を担っています。エルゼビアの事業内容、デジタルソリューション、コンテンツなどの詳細については、www.elsevier.comをご覧ください。